Hypopituitary control and complications study (HypoCCS): a decade of an outcomes assessment observational study.
The Hypopituitary Control and Complications Study (HypoCCS) was set up in 1995 to monitor the long-term efficacy of GH replacement therapy in adult patients with GH deficiency (GHD). The key findings to date have focussed on the diagnosis of GHD, the effects of GH on lean body mass, lipids and bone, and the quality of life benefits. Current guidelines recommend that the diagnosis of adult GHD be proven biochemically. However, these tests are not suitable for all patients, and data from this study suggest that the presence of 3 or more pituitary hormone defects can predict adult GHD with 95% accuracy. The 3-yr efficacy analysis showed that GH replacement therapy in adults is effective in improving body composition, bone mass and lipid profiles, but age is an important factor in determining the response to treatment. Quality of life was improved and maintained during long-term GH replacement therapy in adults. Future results will show if these initial benefits have been sustained.